分機 5213 信箱. 學歷 高雄醫學大學醫學所博士 (2006) 國立成功大學 / 生物化學研究所 (1997) 中山醫學大學醫技系學士

Transcription

1 姓名 葉耀宗 現職 專任教授 分機 5213 信箱 學歷 高雄醫學大學醫學所博士 (2006) 國立成功大學 / 生物化學研究所 (1997) 中山醫學大學醫技系學士 經歷 1. 現職 : 輔英科技大學 / 醫學檢驗生物技術系 / 教授 2014/01 ~ 迄今 2. 經歷 : 輔英科技大學 / 醫學檢驗生物技術系 / 副教授 2011/01 ~ 2014/01 3. 經歷 : 輔英科技大學 / 醫學檢驗生物技術系 / 助理教授 2006/08 ~ 2010/12 4. 經歷 : 輔英科技大學 / 學習輔導組組長 2009/ /10 5. 經歷 : 三元建國高立補習班 / 講師 2002/ /06 6. 經歷 : 高雄醫學大學婦產部 / 研究員 2001/ /06 7. 經歷 : 阮綜合醫院 / 醫檢師 2000/062001/01 學術專長 1. 生物化學 2. 生物技術 3. 腫瘤醫學 4. 藥物開發 5. 分子生物學 開設課程 1. 癌生物學 2. 進階生物化學及實驗 3. 臨床生化分子檢驗及實驗 4. 病理特論 專題 / 論文指導 1. 開發肝癌之新穎性 NBS1-MDM2 交互作用標靶抑制劑 - 戴宏穎 屠凱均 2. 探討 mir-133a 基因群在乳癌中的角色並發展相對非侵犯性篩選平台 (II) 丁毓倫 陳冠婷 3. 組蛋白去乙醯酶 6 之錯位在肺癌轉移的潛在角色 機制探討及治療策略開發 戴宏穎 陳冠婷 4. 探討瘦激素在肝癌中所扮演的角色及應用 (II) 戴宏穎 林建昇 5. 乳癌中組蛋白去乙醯酶媒介之 Her2/neu 核錯位的機制探討與治療策略 張芷瑄 屠凱均 6. 乳癌中 MAPK 媒介之 c-jun 抑制性磷酸化作用的機制探討與預後應用 陳姿妦 丁毓倫 7. 組蛋白去乙醯酶 6 在肝癌中的預後意義與治療策略 戴宏穎 陳冠婷 證照 1. 國家考試院專技高普考 醫檢師 2. 中華企業倫理教育協進會 職場倫理認證 3. CIIP 國際認證中心 3D 列印之時尚流行設計師 產品設計師 3D 列印設計師 1

2 文創設計師 期刊論文 1. SF Yang, MF Hou, FM Chen, OY Fu, YC Wu, CY Chai, YT Yeh (corresponding). Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy. (BMC Cancer Jan 14; 16(1):20.) 2. CJ Yang, YP Liu, HY Dai, YL Shiue, CJ Tsai, MS Huang*, YT Yeh* (co-corresponding). Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer. (Oncotarget Oct 6; 6(30): ) 3. FM Chen, YT Ting, ZF Chen, MF Hou*, YT Yeh* (co-corresponding). Circulating mir-133a as diagnostic and prognostic biomarker for Taiwanese breast cancer. (The breast /S (15) ) 4. SN Wang, KT Lee, CJ Tsai, YJ Chen and YT Yeh (corresponding). Dullaart RP et al. Research update for articles published in EJCI in (Eur J Clin Invest Dec; 42(12): ) 5. SN Wang, KT Lee, CJ Tsai, YJ Chen and YT Yeh (corresponding). Phosphorylated p38 and JNK MAPK Proteins in Hepatocellular Carcinoma. (European Journal of Clinical Investigation Dec; 42(12): ) 6. SN Wang, SF Yang, HH Tsai, KT Lee, YT Yeh (corresponding). Increased adiponectin associated with poor survival in hepatocellular carcinoma. (JOURNAL OF GASTROENTEROLOGY Sep; 49(9): ) 7. YT Yeh (first author), H Yeh, SH Su, JS Lin, KJ Lee, HW Shyu, ZF Chen, SY Huang, SJ Su. Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral cancer cells with varying p53 mutations. (Free Radical Biology & Medicine Sep; 74:1-13.) 8. SF Yang, CW Chang, RJ Wei, YL Shiue, SN Wang*, YT Yeh* (co-corresponding). Involvement of DNA Damage Response Pathways in Hepatocellular Carcinoma. (BioMed Research International. 2014; 2014: ) 9. HY Dai, CY Chien, YT Yeh (corresponding). Histone deacetylase 6 promotes a ligand-independent activation of EGFR signaling in hepatocellular carcinoma. (Journal Of Hepatology Apr; 60:1-S533) 10. YT Yeh (first author, corresponding), HY Dai, CY Chien. Amplification of MPZL1/PZR gene in hepatocellular carcinoma. (Hepatobiliary Surgery and Nutrition Apr; 3(2):87-90.) 11. SH Su, HW Shyu, YT Yeh, KM Chen, H Yeh, SJ Su. Caffeine inhibits adipogenic differentiation of primary adipose-derived stem cells and bone marrow stromal cells. (Toxicology in Vitro Sep; 27(6): ) 12. JH Su, YC Chen, ES Mohamed, YC Du, CW Su, CW Tsao, LL Liu, Y Chou, WB Chang, YD Su, MY Chiang, YT Yeh, MC Lu. Towards the small and the beautiful: a Small Dibromotyrosine Derivative from Pseudoceratina sp. Sponge Exhibits Potent Apoptotic Effect through Targeting IKK/NFκB Signaling Pathway. (Marine drugs Aug 26; 11(9): ) 13. SJ Su*, YT Yeh* (co-first author), SH Su, KL Chang, HW Shyu, KM Chen and H Yeh. Biochanin A promotes osteogenic but inhibits adipogenic differentiation: Evidence with primary adipose-derived stem cells. (Evidence-Based Complementary and Alternative Medicine. 2013; 2013: ) 14. KJ Huang, YC Chen, ES Mohamed, YC Du, JH Su, CW Tsao, WH Yen, WB Chang, YD Su, YT Yeh, MC Lu. 5-Episinuleptolide Acetate, a Norcembranoidal Diterpene from the Formosan Soft Coral Sinularia sp., Induces Leukemia Cell Apoptosis through Hsp90 Inhibition. (Molecules Mar 4; 18(3): ) 2

3 15. MF Hou, FM Chen, YT Yeh (corresponding). Potential role of activated mitogen activated protein kinase kinase 4 in breast cancer. (The Breast Apr 3; 22(13): ) 16. SJ Su, KL Chang, SH Su, YT Yeh, HW Shyu, KM Chen. Caffeine regulates osteogenic differentiation and mineralization of primary adipose-derived stem cells and a bone marrow stromal cell line. (International Journal of Food Sciences and Nutrition Jun; 64(4): ) 17. SJ Su, YT Yeh, HW Shyu. The Preventive Effect of Biochanin A on Bone Loss in Ovariectomized Rats: Involvement in Regulation of Growth and Activity of Osteoblasts and Osteoclasts. (Evidence-Based Complementary and Alternative Medicine. 2013; 2013: ) 18. YT Yeh (first author), CW Chang, RJ Wei, and SN Wang. Progesterone and related compounds in hepatocellular carcinoma: Basic and clinical aspects. (BioMed Research International. 2013; 2013: ) 19. MF Hou, CW Chang, FM Chen, SN Wang, SF Yang, PH Chen, JH Su, YT Yeh (corresponding). Decreased total MKP-1 protein levels predict poor prognosis in breast cancer. (World Journal of Surgery Aug; 36(8): ) 20. YT Yeh* (first author), MJ Chen*, KT Lee, CJ Tsai, HH Lee, SN Wang. The promoting effect of adiponectin in hepatocellular carcinoma. (JOURNAL OF SURGICAL ONCOLOGY Aug 1; 106(2):181-7.) 21. FM Chen, HW Chang, SF Yang, YF Huang, PY Nien, YT Yeh (corresponding), MF Hou. The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer. (Experimental & Molecular Medicine May 31; 44(5): ) 22. YT Yeh* (first author), KT Lee*, CJ Tsai, YJ Chen, SN Wang. Prolactin Promotes Hepatocellular Carcinoma through Janus Kinase 2. (WORLD JOURNAL OF SURGERY May; 36(5): ) 23. ML Chen, CY Chai, KT Yeh, SN Wang, CJ Tsai, YT Yeh* (co-corresponding), SF Yang*. Crosstalk between activated and inactivated c-src in hepatocellular carcinoma. (Disease markers. 2011; 30(6): ) 24. SF Yang, JY Yang, CH Huang, SN Wang, CP Lu, CJ Tsai, CY Chai, YT Yeh (corresponding). Increased Caveolin-1 expression associated with prolonged overall survival rate in hepatocellular carcinoma. (Pathology. 2010; 42(5): ) 25. SN Wang*, YT Yeh* (co-first author), ST Wang, YL Chen, SC Chuang, CG Ker, KT Lee. Decreased retinol binding protein 4 concentrations areassociated with cholesterol gallstone disease. (JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION Jun; 109(6):422-9.) 26. SN Wang*, YT Yeh* (co-first author), ST Wang, KT Lee. Visfatin - a proinflammatory adipokine - in gallstone disease. (American Journal of Surgery Apr; 199(4): ) 27. WW Su, KT Lee, YT Yeh, MS Soon, CL, Wang, ML Yu, SN Wang. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlationstudy. (JOURNAL OF CLINICAL LABORATORY ANALYSIS. 2010; 24(3): ) 28. SF Yang, YT Yeh, SN Wang, SC Hung, WT Chen, CH Huang, CY Chai. SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. (Pathology Oct; 40(6): ) 29. HL Chang, JH Su, YT Yeh, YC Lee, HM Chen, YC Wu, SS Yuan. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo. (Cancer Letters Aug 18; 267(1):85-95.) 3

4 30. HL Chang, YC Wu, JH Su, YT Yeh, SS Yuan. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 MAPK and JNK1/2. (JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Jun; 325(3):841-9.) 31. YT Yeh (first author), OY Fu, IF Chen, MF Hou, SS Yuan. Phospho-JAK1 is aberrantly expressed and is associated with estrogen receptor status in breast cancer. (ONCOLOGY REPORTS Jan; 17(1):35-9.) 32. SN Wang, SC Chuang, YT Yeh, SF Yang, CY Chai, WT Chen, KK Kuo, JS Chen, KT Lee. Potential prognostic value of leptin receptor (Ob-R) in hepatocellular carcinoma. (JOURNAL OF CLINICAL PATHOLOGY Dec; 59(12): ) 33. SF Yang, SS Yuan, YT Yeh, SC Hung, MT Wu, JH Su, CY Chai. Positive association between stat3 and ki-67 in cervical intraepithelial neoplasia. (KAOHSIUNG JOURNAL OF MEDICAL SCIENCES Nov; 22(11): ) 34. SN Wang, YT Yeh, SF Yang, CY Chai, KT Lee. Potential Role of Leptin Expression In Hepatocellular Carcinoma. (JOURNAL OF CLINICAL PATHOLOGY Sep; 59(9):930-4.) 35. SF Yang, SN Wang, YT Yeh, CY Chai, KT Lee. Altered p-stat3 (tyr705) expression is associated with histological grading and intratumor microvessel. (JOURNAL OF CLINICAL PATHOLOGY Jun; 60(6):642-8.) 36. SN Wang, YT Yeh, ML Yu, CL Wang, KT Lee. Serum Adiponectin Between Cholesterol and Pigment Cholelithiasis. (British Journal of Surgery Aug; 93(8):981-6.) 37. DC Chen, YF Chung, YT Yeh, HC Chaung, FC Kuo, OY Fu, HY Chen. Serum adiponectin and leptin levels in Taiwanese breast cancer. (Cancer Letters Jun 8; 237(1): ) 38. YT Yeh (first author), MF Hou, YF Chung, YJ Chen, SF Yang, DC Chen, JH Su, SS Yuan. Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival. (INTERNATIONAL JOURNAL OF CANCER Jun 1; 118(11): ) 39. YT Yeh (first author), OY Fu, IF Chen, SF Yang, YY Wang, HY Chuang, JH Su, MF Hou, SS Yuan. STAT3 Ser727 Phosphorylation and Its Association with Negative Estrogen Receptor Status in Breast Infiltrating Ductal Carcinoma. (INTERNATIONAL JOURNAL OF CANCER Jun 15; 118(12): ) 40. TF Chan, JH Su, YF Chung, YH Hsu, YT Yeh, SS Yuan. Elevated amniotic fluid leptin levels in pregnant women who are destined to develop preeclampsia. (Acta Obstetricia et Gynecologica Scandinavica. 2006; 85(2):171-4.) 41. SN Wang, YT Yeh, ML Yu, WL Chung, KT Lee. Hyperleptinemia and hypoadiponectinemia are associated with gallstone disease. (EUROPEAN JOURNAL OF CLINICAL INVESTIGATION Mar; 36(3): ) 42. SF Yang, SS Yuan, YT Yeh, MT Wu, JH Su, SC Hung, CY Chai. The role of p-stat3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial. (GYNECOLOGIC ONCOLOGY Sep; 98(3): ) 43. SS Yuan, KB Tsai, YF Chung, TF Chan, YT Yeh, LY Tsai, JH Su. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. (GYNECOLOGIC ONCOLOGY Mar; 92(3): ) 44. TF Chan, SS Yuan, HS Chen, CF Guu, LC Wu, YT Yeh, YF Chung, SB Jong, JH Su. Correlations between umbilical and maternal serum adiponectin levels and neonatal birthweights. (Acta Obstetricia et Gynecologica Scandinavica Feb; 83(2):165-9.) 45. TF Chan, JH Su, YF Chung, YH Hsu, YT Yeh, SB Jong, SS Yuan. Amniotic fluid and maternal serum leptin levels in pregnant women who subsequently develop 4

5 preeclampsia. (European Journal of Obstetrics & Gynecology and Reproductive Biology May 1; 108(1):50-3.) 46. SS Yuan, HL Chang, HW Chen, YT Yeh, YH Kao, KH Lin, YC Wu, JH Su. Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase-3-related pathway. (LIFE SCIENCES May 9; 72(25): ) 47. SS Yuan, YT Yeh, EY Lee. Pax-2 interacts with RB and reverses its repression on the promoter of Rig-1,a Robo member. (Biochemical and Biophysical Research Communications Aug 30; 296(4): ) 研討會論文 1. Inter-alpha-trypsin inhibitor heavy chain-5 (ITIH-5) gene is a potential methylation biomarker in breast cancer. (2014, May) Taiwan Joint Cancer Conference and International Conference of the Asian Clinical Oncology (TJCC & ACOS). Taipei, Taiwan. 2. Histone deacetylase 6 promotes a ligand-independent activation of EGFR signaling in hepatocellular carcinoma. (2014, Apr) European Association for the Study of the Liver. London, United Kingdom. 3. Increased pre-mir-133a expression associated with poor prognosis in Taiwanese breast cancer. (2013, Mar) Taiwan Surgical Association. Taipei, Taiwan. 4. Study the underlying mechanisms and potential roles of activated Mitogen-avtivated Protein Kinase Kinase4 (p-mkk4) in breast cancer metastasis. (2013, Mar) Gallen International Breast Cancer Conference. St. Gallen, Switzerland. 5. HDAC2 promotes the nuclear the nuclear translocation of HER-2/neu and induced the expression of COX-2 in breast cancer. (2012, Sep) TIBCS & IOPBS. Taipei, Taiwan. 6. PIAS3 and its interplay with estrogen receptor in breast cancer. (2012, May) EMBO Conference Cellular Signaling & Molecular Medicine. Dubrovnik, Croatia. 7. Interplay of HDAC6 with progesterone signaling in breast cancer. (2012, May) EMBO Conference Cellular Signaling & Molecular Medicine. Dubrovnik, Croatia. 8. Novel peptide mimics targeting Nibrin inhibit tumor growth of liver cancer cells. (2012, May) EMBO Conference Cellular Signaling & Molecular Medicine. Dubrovnik, Croatia. 9. Increased HDAC8 protein associates with poor survival of breast cancer patients. (2012, May) International Symposium on Clinical and Translational Cancer Research. Kaohsiung, Taiwan. 10. Lignad-like peptide mimic enhanced the cytotoxicity of medroxylprogesterone and mgesterol acetate toward liver cancer cells. (2012, May) International Symposium on Clinical and Translational Cancer Research. Kaohsiung, Taiwan. 11. The crosstalk of HDAC2 and HER2/neu signaling in breast cancer. (2012, Mar) Taiwan Surgical Association. Taipei, Taiwan. 12. The Interplay of Methylation of mkp-1 Promoter with Estrogen receptor in Breast Cancer. (2012, Mar) Taiwan Surgical Association. Taipei, Taiwan. 13. Increased HDAC6 Associated with β-catenin and Poor Prognosis in Hepatocellular Carcinoma. (2011, May) European Biomarkers Summit. London, United Kingdom. 14. The HDAC9-MEF2 regulatory cycle in metastatic breast cancer. (2010, Dec) San Antonio Breast Cancer Symposia. Texas. 15. The interplay of HDAC2 with HER2/neu in breast cancer. (2010, Sep) Taipei 5

6 International Breast Cancer Symposium. Taipei, Taiwan. 16. Histone deacetylase 6 was associated with overall survival rate in progesterone receptor-negative breast cancer. (2010, Mar) New Paradigms in Cancer Therapeutics (Z1). Victoria, British Columbia. 17. Molecular pathways and therapeutic targets of adiponectin in Hepatocellular carcinoma. (2010, Mar) New Paradigms in Cancer Therapeutics (Z1). Victoria, British Columbia. 研究計畫 Principal investigator of Ministry Of Science and Technology 1. Title:The role and the underlying mechanism of stress activated protein kinase (SAPK) signaling and its interplay with sex hormones in breast cancer. (NSC B ) Funding Period: ~ (NTD. 1,000,000 / 1 year) 2. Title:The role of stress activated protein kinase (SAPK) signaling in breast cancer development: clinical application and basic study. (NSC B MY3) Funding Period: ~ (NTD. 3,881,000 / 3 years) 3. Title:Develop novel drugs targeting Nibrin/NBS1, based on its clinical implications and underlying mechanisms in hepatocellular carcinoma. (NSC B MY3) Funding Period: ~ (NTD. 4,560,000 / 3 years) 4. Title: Study and pro-drug development of nuclease Mre11-mediated activation of AKT signaling in hepatocellular carcinoma. (NSC B ) Funding Period: ~ (NTD. 830,000 / 1 year) 5. Title:Prognostic relevance and therapeutic strategy of histone deacetylase 6 in hepatocellular carcinoma. (MOST B ) Funding Period: ~ (NTD. 4,272,359 / 1 year) 6. Title:Prognostic relevance and therapeutic strategy of histone deacetylase 6 in hepatocellular carcinoma (II) (MOST B ) Funding Period: ~ (NTD. 600,000 / 1 year) Co-principal investigator of Ministry Of Science and Technology 1. Title:The interplay of leptin and progesterone and their applications in HCC. (NSC B MY3) Funding Period: ~ (NTD. 3,660,000 / 3 years) 2. Title:The role of STAT3-MAPK signaling in breast cancer. (NSC B MY3) Funding Period: ~ (NTD. 4,760,000 / 3 years) 6

7 3. Title:Mre11 / Rad50 / NBS1 complex in breast cancer: basic study and clinical application. (NSC B MY2) Funding Period: ~ (NTD. 2,040,000 / 2 years) 4. Title:From clinic to basic study to overview the impact of adiponectin on hepatocellular carcinoma. (NSC B MY2) Funding Period: ~ (NTD. 1,980,000 / 2 years) 5. Title:Combine clinical evidence with basic research to explore the role and application of DNA repair protein, RAD51, in hepatocellular carcinoma. (NSC B MY3) Funding Period: ~ (NTD. 3,870,000 / 3 years) 6. Title:Study the interplay of HDAC6 with estrogen receptor for clinical applications in breast cancer. (NSC B MY3) Funding Period: ~ (NTD. 3,870,000 / 3 years) 7. Title:Mechanism study and potential application of dual-specificity MAP kinase phosphatase1(mkp1/dusp1) in breast cancer. (NSC B MY3) Funding Period: ~ (NTD. 3,270,000 / 3 years) 8. Title:Potential roles, underlying mechanisms, and therapeutic strategies for mis-localization of HDAC 6 in lung cancer metastasis. (NSC B MY3) Funding Period: ~ (NTD. 3,750,000 / 3 years) 9. Title:Study of Mir133a clusters and development of relative non-invasive screen platform in breast cancer. (NSC B ) Funding Period: ~ (NTD. 1,000,000 / 1 year) 10. Title:Study and application of leptin in hepatocellular carcinoma. (NSC B MY3) Funding Period: ~ (NTD. 3,900,000 / 3 years) 11. Title:Therapeutic strategy and mechanistic study for HDACs-mediated nuclear mislocalization of Her2/neu in breast cancer. (NSC B MY3) Funding Period: ~ (NTD. 3,900,000 / 3 years) 12. Title:Mechanistic study and prognostic application of MAPK-mediated inhibitory phosphorylation of c-jun in breast cancer. (NSC B MY3) Funding Period: ~ (NTD. 3,600,000 / 3 years) 13. Title:Study of mir-133a clusters and development of relative non-invasive 7

8 專利 screen platform in breast cancer (II). MOST B MY2 Funding Period: ~ (NTD. 2,340,000 / 2 years) Industry-University Collaboration Projects with National of China Medical University, Taiwan. (Yang-Chang Wu) 1. Title:Development of novel protein-protein interaction inhibitors targeting NBS1- MDM2 in hepatocellular carcinoma. (MOST B CC1) Funding Period: ~ (NTD. 4,272,359 / 1 year) Ministry of Education and Asia-pacific Biotech Developing 1. Title:Improvement and study of a novel MDM-2 mimic peptide which can selectively suppress breast cancer cells but not immortalized breast cells. Funding Period: ~ (NTD. 1,610,000) 2. Title:Determine the structure-activity relationship of anti-cancer peptide mimetic in vitro and in vivo. Funding Period: ~ (NTD. 1,780,000) 3. Title:Development and application of ligand-like anti-cancer peptide mimics in hepatocellular carcinoma. Funding Period: ~ (NTD. 1,928,000) PCT/CN2010/ 以瘦激素治療肝癌用途之應用 榮譽事蹟 1. 教育部大專院校實施特殊優秀人才彈性薪資方案二起 (2013 ~ 2015) 2. 榮登 Marquis Who s Who in the World 世界名人錄 (2012 年 ~ 迄今 ) 3. 連續獲得科技部補助大專校院獎勵特殊優秀人才六起 (2010 ~ 2016) 4. 輔英校內 學年度教師評鑑研究類優良獎 ( ) 5. Stryers 生物化學專書之譯者 ISBN: (2008) 6. 擔任國際知名 SCI 期刊 (Oncotarget Cancer Letters Carcinogenesis 及 Neoplasia 等 ) 之審稿委員 (reviewer) (2007 ~ 迄今 ) 7. 擔任國際知名期刊 International Journal of Clinical and Experimental Pathology (IJCEP) International Scholarly Research Network (ISRN) 和 Advances in Modern Oncology Research (AMOR) 之編輯委員 (Editor) (2007 ~ 迄今 ) 8